NCT02314923View on ClinicalTrials.gov

Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)

PHASE1CompletedINTERVENTIONAL
Enrollment

513

Participants

Timeline

Start Date

December 5, 2014

Primary Completion Date

June 23, 2016

Study Completion Date

June 23, 2016

Conditions
Ebola Virus
Interventions
BIOLOGICAL

V920 Vaccine

Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

OTHER

Placebo

0.9% Saline

Sponsors
All Listed Sponsors
collaborator

BioProtection Systems Corporation

INDUSTRY

collaborator

Department of Health and Human Services

FED

lead

Merck Sharp & Dohme LLC

INDUSTRY